Executive Medical Director Otto Bock HealthCare LP Austin, TX, Texas, United States
This study analyzed medical cost of 10,147 persons with transfemoral amputation and K2 mobility using NMPKs and 7,796 persons with TF amputation and K3 mobility using MPKs in the Medicare Master Beneficiary Summary File and Medicare Fee-for-Service Claims Database. Modeling assuming similar adoption of MPKs in the K2 population as previously in the K3 population showed that Medicare would save $410 million over a 10-year period by providing MPKs to K2 patients.
Learning Objectives:
discuss the differences in medical and prosthetic cost incurred by Medicare between K2 patients with transfemoral amputation using NMPKs and K3 patients using MPKs.
discuss the expected Medicare savings in medical cost by providing MPKs to the K2 patient population with transfemoral amputation over a 10-year period.
discuss the expected reduction in K2 patients who experience injurious falls resulting in medical claims by providing MPKs.
